Taking Zometa or the drug used to medicate and strengthen the bone can be a lot of help to fight the metastatic breast cancer before the surgery.

It is the complexity of the breast cancer wherein the cancerous cells are already spreading in the other parts of the body. According to the University School of Medicine in St. Louis, patients that are taking this kind of drug three months ahead before the surgery for breast cancer will do a good medication because it can lower the number of tumor cells in the bone marrow.

Disseminated Tumor Cells (DTCs) are tumors that scatter everyday with thousands of tumor cells in the body.  The DTCs of breast cancer are sometimes associated in the bone marrow when the growth of the bone helps them to survive.

Patients that undergo chemotherapy can expand the turnover of the bone and the growth factors of it. It is possible to intensify the problem of disseminated tumor cells in the bone, which can cause the patients to have a metastatic illness in breast cancer.

The DTCs sanctuary is the bone marrow itself. It allows them to scatter and circulate in the different body organs that can lead to patient’s sudden death. According to Dr. Rebecca Aft, a professor and specialist in cancer of the breast in Alvin J. Siteman Cancer Center and in the Medical School in Washington University believed that Zometa suppress the growing factors to help support the expansion of DTCs.

Zometa also known as zoledronic acid is advised to lower and stop the complications in the bone because of many bone metastases and myeloma that comes from solid tumors. In addition to this, two researches have shown that Zometa helps the free survival of the disease when taken along with estrogen-lowering therapy before the surgery in the breast cancer.

The results of these studies are proven to improve and help the patient’s condition to reduce the tumor cells and to stop the spreading of the tumor cells in the other parts of the body.